Document is current
Any future updates will be listed below
-
Authors
Pardo, Jèssica
Roura, Ignacio
Montal, Victor
Martín-Barceló, Cristina
Oltra, Javier
Campabadal, Anna
Bargalló, Núria
Serradell, Mònica
Mayà, Gerard
Montini, Angelica
Gaig, Carles
Pont-Sunyer, Claustre
Fortea, Juan
Iranzo, Alex
Junqué, Carme
Segura, Bàrbara
-
Funding
Funding for this research was provided by:
Ministerio de Ciencia e Innovación (PRE2021-099674, CEX2021-001159-M, CEX2021-001159-M, CEX2021-001159-M)
'la Caixa' Foundation (LCF/BQ/DR22/11950012)
Instituto de Salud Carlos III (FI18/00275, PI20/01473)
Ministerio de Ciencia, Innovación y Universidades (PRE2018-086675)
National Institutes of Health (1R01AG056850-01A1)
Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151)
Horizon 2020 Framework Programme (H2020-SC1-BHC-2018-2020)
Generalitat de Catalunya (SGR 2021SGR00801, SGR 2021SGR00801)
Ministerio de Economía y Competitividad (PID2020-114640GB-I00, PID2020-114640GB-I00)
- License Information
-
More Information
Article History
Received: 11 February 2025
Accepted: 16 June 2025
First Online: 3 July 2025
Competing interests
: J.F. reported receiving personal fees for service on the advisory boards, adjudication committees, or speaker honoraria from AC Immune, Alzheon, Novartis, Lundbeck, Roche, Fujirebio, and Biogen, outside the submitted work. J.F. reports holding a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx, EPI8382175.0). All other authors declare no competing interests.
